SynthesisOrphanet journal of rare diseases2026
Psychiatric manifestations in Neuronal ceroid lipofuscinoses.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeuronal ceroid lipofuscinoses (NCLs) are rare genetic neurodegenerative disorders characterized by progressive cognitive, motor, and visual decline. The transition from supportive care to emerging disease-modifying therapies has reshaped the clinical landscape of NCLs and highlighted the urgent need for sensitive and clinically meaningful outcome measures beyond traditional motor and survival endpoints. Psychiatric manifestations, which profoundly affect daily functioning and quality of life, represent a potentially valuable yet underexplored domain.
methodsWe conducted a systematic review following PRISMA guidelines to synthesize current evidence on the prevalence, clinical spectrum, developmental trajectories, assessment strategies, and management of psychiatric manifestations across NCL subtypes.
resultsPsychiatric symptoms are highly prevalent across NCL forms and encompass a broad clinical spectrum, including early emotional and behavioral dysregulation, neurodevelopmental-like features, anxiety and depressive symptoms, obsessive-compulsive phenomena, and psychotic-spectrum manifestations. Their expression varies according to age and disease stage and reflects a multifactorial interplay between neurodegeneration, disrupted neurodevelopment, autonomic and sensory dysfunction, cognitive decline, genetic modifiers, and environmental factors. Despite their clinical relevance, management remains largely empirical and palliative, relying on psychotropic medications and supportive interventions with limited evidence and frequent adverse effects. Furthermore, psychiatric assessment tools are inconsistently applied, predominantly in CLN3 disease, and terminology remains heterogeneous and non-standardized, hindering cross-study comparability and robust phenotypic characterization.
conclusionsPsychiatric manifestations represent a core and developmentally modulated component of NCLs. The lack of standardized language and validated, age-appropriate assessment instruments constitute a major barrier to clinical care and research. Systematic phenotyping and harmonized measurement strategies are urgently needed to improve management and to integrate psychiatric outcomes into future natural history studies and therapeutic trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.